A funding opportunity to amplify medical and financial benefits of precision medicine
Acobiom’s predictive diagnostic tests are part of a new generation of complex and high value-added molecular diagnostics. These blood-based diagnostic tests will improve the patient’s medical care in identifying those who are most likely to benefit from pre-determined treatments, while optimizing health care costs.
Blood‐based diagnostic tests dedicated to precision medicine
Acobiom is currently involved in the development of innovative Medical Diagnostics that can predict individual response of patients to certain treatments. These diagnostic tests focused on Precision Medicine concern diseases with unmet medical needs.
Acobiom’s diagnostic tests are non-invasive and can be performed from a simple blood sample (liquid biopsy). These tests are based on the measurement and the analysis (by proprietary algorithms) of a combination of several patented biological (molecular) markers. These Blood‐based Diagnostic Tests have been developing for routine uses on platforms already employed in central labs and clinical centers.
The benefits of Acobiom’s In-Vitro Diagnostic (IVD) tests are helping choose the most adapted therapy, improving the patient’s quality of life and its overall care during treatment, avoiding treatment resistance, reducing adverse effects and toxicities, avoiding ineffective, uncomfortable and expensive treatments and, overall, improving the patient’s medical care.
A new generation of high added value molecular diagnostics
Whatever the therapeutic domain, several diagnostics capable to predict patient response to a predetermined treatment are already on the market. These predictive diagnostic tests are provided by companies as: Agendia, Genomic Health, Myriad Genetic, Qiagen, Roche, etc.
Acobiom’s predictive diagnostic tests are part of a new generation of complex and high added value molecular Diagnostics. Some of these IVD are really gainful (see the graphs below): they showed impressive growing revenues as: Oncotype DX (Genomic Health) or AlloMap (CareDX).
A diagnostic portfolio dedicated to improve the patient’s medical care
In oncology domain, in which Acobiom will commercialize its first diagnostics, the global market for Companion Diagnostic tests (predictive diagnostics of response to a predetermined treatment) has been estimated at US$3.5 billion in 2016, and is likely to reach US$13.6 billion by 2025 (source: Transparency Market Research).
GemciTest® will be the first Acobiom’s predictive diagnostic test on the market. Focused on pancreatic cancer, the commercialization of this IVD is forecasted within the next year.
Moreover, the company will soon develop in-vitro diagnostics that will predict patient resistance to 1st line treatments in breast, lung and pancreatic cancers. Acobiom obtained a Bpifrance funding associated with this new R&D program called Oncosnipe.
The future diagnostics developed in this Oncosnipe project will grow the pipeline of diagnostics of the company and complete GemciTest in marketing and medical points of view.
Partners interested in the funding opportunity proposed today by Acobiom to amplify medical and financial benefits of precision medicine can contact the company to obtain more information or to read its Executive Summary.